Traders purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading hours on Monday. $133.52 million flowed into the stock on the tick-up and $78.12 million flowed out of the stock on the tick-down, for a money net flow of $55.40 million into the stock. Of all companies tracked, Gilead Sciences had the 10th highest net in-flow for the day. Gilead Sciences traded down ($0.04) for the day and closed at $79.02

A number of research firms have weighed in on GILD. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Tuesday. Wells Fargo & Co raised Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their target price for the company from $79.02 to $96.00 in a research report on Tuesday. Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the company a “hold” rating in a research report on Wednesday, January 3rd. BMO Capital Markets reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, January 3rd. Finally, Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $85.61.

The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The stock has a market cap of $104,800.00, a PE ratio of 9.13, a PEG ratio of -1.68 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s revenue was down 13.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.75 EPS. analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.59%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.

In related news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 491,666 shares of company stock worth $36,442,567. Corporate insiders own 1.30% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Welch Investments LLC bought a new position in Gilead Sciences during the 3rd quarter worth $108,000. Wealthcare Advisory Partners LLC bought a new position in Gilead Sciences during the 3rd quarter worth $133,000. Horan Capital Advisors LLC. bought a new position in Gilead Sciences during the 3rd quarter worth $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Gilead Sciences during the 2nd quarter worth $147,000. Finally, Hanson & Doremus Investment Management grew its stake in shares of Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares in the last quarter. Hedge funds and other institutional investors own 75.95% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/01/17/traders-buy-shares-of-gilead-sciences-gild-on-weakness.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.